An Observational, Register-based Study on Ticagrelor 60 mg Persistence and Event Rates in Clinical Practice in the US and Europe
Latest Information Update: 12 May 2022
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin
- Indications Cardiovascular disorders; Myocardial infarction; Stroke
- Focus Adverse reactions
- Acronyms ALETHEIA
- Sponsors AstraZeneca
- 04 Apr 2022 Results presented at the 71st Annual Scientific Session of the American College of Cardiology
- 23 Aug 2021 According to an AstraZeneca media release, data from this trial will be presented at ESC Congress 2021 organised annually by the European Society of Cardiology (ESC)
- 08 Aug 2021 Trial design, published in the Clinical Cardiology.